Clinical therapeutic effects of combined methotrexate and other chemotherapeutic agents in treating children and young patients with osteosarcoma: A protocol for systematic review and meta-analysis.
Adolescent
Antineoplastic Agents
/ administration & dosage
Bone Neoplasms
/ drug therapy
Child
Drug Therapy, Combination
Female
Humans
Male
Meta-Analysis as Topic
Methotrexate
/ administration & dosage
Osteosarcoma
/ drug therapy
Randomized Controlled Trials as Topic
Research Design
Systematic Reviews as Topic
Treatment Outcome
Young Adult
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
30 Apr 2021
30 Apr 2021
Historique:
received:
28
03
2021
accepted:
30
03
2021
entrez:
28
4
2021
pubmed:
29
4
2021
medline:
5
5
2021
Statut:
ppublish
Résumé
Osteosarcoma is one of the most common primary bone tumour in children and young patients, and the third most common among adults. Its main treatment option is currently based on neoadjuvant or adjuvant chemoradiotherapy along with the lesion's surgical resection. The current study's primary aim is to examine the clinical therapeutic impacts of combined methotrexate, along with other chemotherapeutic agents to treat children and young adults suffering from osteosarcoma. We will perform a comprehensive literature search in English database (PubMed, EMBASE, Cochran Library CINAHL, and PsycINFO) and Chinese database (Chinese National Knowledge Infrastructure, VIP information database, Chinese Biomedical Database, and WanFang Database) with no language restriction from their inception to the search date. Additionally, two independent authors will screen the works of literature obtained from these databases, obtain information, and examine the risks of data included for the studies' bias. Furthermore, we intend to employ the Q statistics as well as I2 statistics to calculate heterogeneity among each study's analysis. Accordingly, we will utilize the funnel plots and Egger test to assess the possibility of publication bias where relevant. The current study aims to provide significant information regarding the clinical therapeutic impacts of combines methotrexate along with other chemotherapeutic agents to treat children and young adults suffering from osteosarcoma. The present study will generate compelling evidence of combined methotrexate as well as other chemotherapeutic agents for osteosarcoma among children and young adults. Also, it will provide clinical practice suggestions. The study is founded upon published data. Therefore, there is no requirement for ethics approval. March 26, 2021.osf.io/a23rc. (https://osf.io/a23rc/).
Sections du résumé
BACKGROUND
BACKGROUND
Osteosarcoma is one of the most common primary bone tumour in children and young patients, and the third most common among adults. Its main treatment option is currently based on neoadjuvant or adjuvant chemoradiotherapy along with the lesion's surgical resection. The current study's primary aim is to examine the clinical therapeutic impacts of combined methotrexate, along with other chemotherapeutic agents to treat children and young adults suffering from osteosarcoma.
METHODS
METHODS
We will perform a comprehensive literature search in English database (PubMed, EMBASE, Cochran Library CINAHL, and PsycINFO) and Chinese database (Chinese National Knowledge Infrastructure, VIP information database, Chinese Biomedical Database, and WanFang Database) with no language restriction from their inception to the search date. Additionally, two independent authors will screen the works of literature obtained from these databases, obtain information, and examine the risks of data included for the studies' bias. Furthermore, we intend to employ the Q statistics as well as I2 statistics to calculate heterogeneity among each study's analysis. Accordingly, we will utilize the funnel plots and Egger test to assess the possibility of publication bias where relevant.
RESULTS
RESULTS
The current study aims to provide significant information regarding the clinical therapeutic impacts of combines methotrexate along with other chemotherapeutic agents to treat children and young adults suffering from osteosarcoma.
CONCLUSIONS
CONCLUSIONS
The present study will generate compelling evidence of combined methotrexate as well as other chemotherapeutic agents for osteosarcoma among children and young adults. Also, it will provide clinical practice suggestions.
ETHICS AND DISSEMINATION
BACKGROUND
The study is founded upon published data. Therefore, there is no requirement for ethics approval.
OSF REGISTRATION NUMBER
UNASSIGNED
March 26, 2021.osf.io/a23rc. (https://osf.io/a23rc/).
Identifiants
pubmed: 33907104
doi: 10.1097/MD.0000000000025564
pii: 00005792-202104300-00019
pmc: PMC8084082
doi:
Substances chimiques
Antineoplastic Agents
0
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25564Subventions
Organisme : Henan Provincial Health Science and Technology Innovative Talent Project
ID : 4115
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Oncol Lett. 2018 Nov;16(5):6228-6237
pubmed: 30405759
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95
pubmed: 30285218
Ann Diagn Pathol. 2020 Dec;49:151654
pubmed: 33130384
Cancer. 2005 Nov 15;104(10):2214-21
pubmed: 16206297
Cancer. 2009 Apr 1;115(7):1531-43
pubmed: 19197972
Cancer. 1985 Oct 1;56(7):1515-21
pubmed: 3861228
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Cancers (Basel). 2020 Jul 31;12(8):
pubmed: 32751922
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Oncologist. 2004;9(4):422-41
pubmed: 15266096
J Natl Cancer Inst. 1959 Apr;22(4):719-48
pubmed: 13655060
J Clin Oncol. 2015 Sep 20;33(27):3029-35
pubmed: 26304877
Orphanet J Rare Dis. 2007 Jan 23;2:6
pubmed: 17244349
Contemp Clin Trials. 2015 Nov;45(Pt A):139-45
pubmed: 26343745
Curr Opin Pediatr. 2016 Feb;28(1):26-33
pubmed: 26626558